1887

Journal of Medical Microbiology logo

Volume 38, Issue 2

Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by in a rat model Free

Abstract

Summary

The protective efficacies of eight vaccine preparations consisting of outer-membrane protein F, elastase and exotoxin A toxoid, administered either individually or in various combinations, were determined in a rat model of chronic pulmonary infection. Rats were immunised intramuscularly at 2-week intervals (days 0, 14 and 28). On day 42, blood was collected and antisera were obtained from each vaccine group for use in an enzyme-linked immunosorbent assay which determined the titre of IgG antibodies elicited by each vaccine. Also on day 42, rats were challenged by intratracheal inoculation of a clinical isolate of encased within agar beads. On day 49, the animals were killed and the lungs were examined macroscopically for the presence of lesions and fixed for histological examination. When compared with control rats immunised with bovine serum albumin, rats immunised with protein F alone as a vaccine received significant protection against the development of severe pulmonary lesions. Elastase used alone as a vaccine provided some protection against severe lung lesions and reduced the incidence of microscopic peribronchial inflammation. However, the combination of protein F plus elastase as a vaccine did not afford protection from severe lesions, and there was an increased incidence of necrotising granulomas in the lungs from this vaccine group. Protection against lung lesions from the three-component vaccine consisting of protein F, elastase and exotoxin A toxoid was similar, to that provided by the protein F vaccine. Neither macroscopic nor histological evidence showed any enhancement of protective efficacy for the three-component vaccine over that of the protein F vaccine. No combinatination of elastase or exotoxin A toxoid with protein F improved the protective efficacy of the protein F vaccine alone.

  • Received:
  • Accepted:
  • Published Online:
© Society for General Microbiology, 1993
Loading

Article metrics loading...

/content/journal/jmm/10.1099/00222615-38-2-79
1993-02-01
2024-04-23
Loading full text...

Full text loading...

/deliver/fulltext/jmm/38/2/medmicro-38-2-79.html?itemId=/content/journal/jmm/10.1099/00222615-38-2-79&mimeType=html&fmt=ahah

References

  1. Gilleland HE, Parker MG, Matthews JM, Berg RD. Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice. Infect Immun 1984; 44:49–54
     [Google Scholar]
  2. Matthews-Greer JM, Gilleland HE. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. J Infect Dis 1987; 155:1282–1291
     [Google Scholar]
  3. Matthews-Greer JM, Robertson DE, Gilleland LB, Gilleland HE. Pseudomonas aeruginosa outer membrane protein F produced in Escherichia coli retains vaccine efficacy. Curr Microbiol 1990; 20:171–175
     [Google Scholar]
  4. Gilleland HE, Gilleland LB, Matthews-Greer JM. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model. Infect Immun 1988; 56:1017–1022
     [Google Scholar]
  5. Gilleland HE, Gilleland LB, Hughes EE, Matthews-Greer JM. Recombinant outer membrane protein F of Pseudomonas aeruginosa elicits antibodies that mediate opsono-phagocytic killing, but not complement-mediated bacteriolysis of various strains of P. aeruginosa. Curr Microbiol 1992; 24:1–7
     [Google Scholar]
  6. Zach MS. Pathogenesis and management of lung disease in cystic fibrosis. J Roy Soc Med 1991; 84:S1810–17
     [Google Scholar]
  7. Hoiby N, Koch C. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax 1990; 45:881–884
     [Google Scholar]
  8. Woods DE, Cryz SJ, Friedman RL, Iglewski BH. Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats. Infect Immun 1982; 36:1223–1228
     [Google Scholar]
  9. Wretlind B, Pavlovskis OR. Pseudomonas aeruginosa elastase and its role in Pseudomonas infections. Rev Infect Dis 1983; 5:Suppl 5S998–S1004
     [Google Scholar]
  10. Kharazmi A. Mechanisms involved in the evasion of the host defence by Pseudomonas aeruginosa. Immunol Lett 1991; 30:201–206
     [Google Scholar]
  11. Iglewski BH, Sadoff JC. Toxin inhibitors of protein synthesis: production, purification, and assay of Pseudomonas aeruginosa toxin A. In: Moldave K, Grossman L. (eds) Methods in enzymology New York: Academic Press; 1979; LX780–793
     [Google Scholar]
  12. Morihara K. Production of elastase and proteinase by Pseudo monas aeruginosa. J Bacterial 1964; 88:745–757
     [Google Scholar]
  13. Markwell MAK, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978; 87:206–210
     [Google Scholar]
  14. Klinger JD, Cash HA, Wood RE, Miler JJ. Protective immuni zation against chronic Pseudomonas aeruginosa pulmonary infection in rats. Infect Immun 1983; 39:1377–1384
     [Google Scholar]
  15. Schaad UB, Lang AB, Wedgwood J. et al. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 1991; 338:1236–1237
     [Google Scholar]
  16. Pier GB, Small GJ, Warren HB. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science 1990; 249:537–540
     [Google Scholar]
  17. Hancock REW, Mutharia LM, Chan L, Darveau RP, Speert DP, Pier GB. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun 1983; 42:170–177
     [Google Scholar]
  18. Luzar MA, Montie TC. Avirulence and altered physiological properties of cystic fibrosis strains of Pseudomonas aeruginosa. Infect Immun 1985; 50:572–576
     [Google Scholar]
  19. Pier GB, DesJardins D, Aguilar T, Barnard M, Speert DP. Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients. J Clin Microbiol 1986; 24:189–196
     [Google Scholar]
  20. Yoshimura F, Zalman LS, Nikaido H. Purification and properties of Pseudomonas aeruginosa porin. J Biol Chem 1983; 258:2308–2314
     [Google Scholar]
  21. Lambert PA, Booth BR. Exposure of outer membrane proteins on the surface of Pseudomonas aeruginosa PAOl revealed by labeling with [125I]lactoperoxidase. FEMS Microbiol Lett 1982; 14:43–45
     [Google Scholar]
  22. Mutharia LM, Hancock REW. Surface localization of Pseudo monas aeruginosa outer membrane porin protein F by using monoclonal antibodies. Infect Immun 1983; 42:1027–1033
     [Google Scholar]
  23. Mutharia LM, Nicas TI, Hancock REW. Outer membrane proteins of Pseudomonas aeruginosa serotype strains. J Infect Dis 1982; 146:770–779
     [Google Scholar]
  24. Counts GW, Schwartz RW, Ulness BK. et al. Evaluation of an immunofluorescent-antibody test for rapid identification of Pseudomonas aeruginosa in blood cultures. J Clin Microbiol 1988; 26:1161–1165
     [Google Scholar]
  25. Battershill JL, Speert DP, Hancock REW. Use of monoclonal antibodies to protein F of Pseudomonas aeruginosa as opsonins for phagocytosis by macrophages. Infect Immun 1987; 55:2531–2533
     [Google Scholar]
  26. Que JU, Woods DE. Alteration of lung structure and function by Pseudomonas aeruginosa. Pathol Immunopathol Res 1987; 6:93–102
     [Google Scholar]
  27. Williams JC, Lucas BJ, Knee C, Renzetti M, Donahue J. Acute lung injury induced by Pseudomonas aeruginosa elastase in hamsters. Exp Lung Res 1992; 18:155–171
     [Google Scholar]
  28. Elborn JS, Shale DJ. Lung injury in cystic fibrosis. Thorax 1990; 45:970–973
     [Google Scholar]
  29. Döring G. Microbial lung infections: new therapeutic strategies. Pathol Biol 1991; 39:587–591
     [Google Scholar]
  30. Bjorn MJ, Vasil ML, Sadoff JC, Iglewski BH. Incidence of exotoxin production by Pseudomonas species. Infect Immun 1977; 16:362–366
     [Google Scholar]
  31. Woods DE, Schaffer MS, Rabin HR, Campbell GD, Sokol PA. Phenotypic comparison of Pseudomonas aeruginosa strains isolated from a variety of clinical sites. J Clin Microbiol 1986; 24:260–264
     [Google Scholar]
  32. Burke V, Robinson JO, Richardson CJL, Bundell CS. Longi tudinal studies of virulence factors of Pseudomonas aeruginosa in cystic fibrosis. Pathology 1991; 23:145–148
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/00222615-38-2-79
Loading
Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model
J. Med. Microbiol. 38, 79 (1993); https://doi.org/10.1099/00222615-38-2-79
/content/journal/jmm/10.1099/00222615-38-2-79
/content/journal/jmm/10.1099/00222615-38-2-79
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error